|
ERLIN2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.79578574233119E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.123634601503E-12 |
| Normal-vs-Stage2 |
1.16370000302624E-08 |
| Normal-vs-Stage3 |
1.11022302462516E-15 |
| Normal-vs-Stage4 |
4.44089209850063E-16 |
| Stage1-vs-Stage2 |
3.352200E-01 |
| Stage1-vs-Stage3 |
2.924400E-03 |
| Stage1-vs-Stage4 |
2.056100E-03 |
| Stage2-vs-Stage3 |
3.184000E-03 |
| Stage2-vs-Stage4 |
9.214500E-04 |
| Stage3-vs-Stage4 |
4.207000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
7.11652958784725E-14 |
| Normal-vs-AfricanAmerican |
1.54046999999435E-05 |
| Normal-vs-Asian |
3.37874173084174E-12 |
| Caucasian-vs-AfricanAmerican |
3.035800E-01 |
| Caucasian-vs-Asian |
6.862400E-01 |
| AfricanAmerican-vs-Asian |
5.452400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.63247193540883E-12 |
| Normal-vs-Female |
2.28095320409238E-12 |
| Male-vs-Female |
4.266000E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.60802490714696E-12 |
| Normal-vs-Age(41-60Yrs) |
1.78412840057263E-12 |
| Normal-vs-Age(61-80Yrs) |
1.62625468647093E-12 |
| Normal-vs-Age(81-100Yrs) |
1.828880E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.993800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.253800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.661400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.637400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.111800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.507200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.64616999999145E-05 |
| Classical-VS-Follicular |
1.274000E-01 |
| Classical-VS-Other |
5.322800E-01 |
| Classical-VS-Normal |
4.8097081872811E-12 |
| Tall-VS-Follicular |
1.79330000005251E-06 |
| Tall-VS-Other |
1.987210E-01 |
| Tall-VS-Normal |
1.62447832963153E-12 |
| Follicular-VS-Other |
3.020200E-01 |
| Follicular-VS-Normal |
8.25000068260806E-11 |
| Other-VS-Normal |
4.231900E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
<1E-12 |
| Normal-vs-N1 |
1.62470037423645E-12 |
| N0-vs-N1 |
2.556500E-03 |
|
|
